Top Picks For Chinese Medicine Brands By Oppenheimer
American Oriental Bioengineering, Inc. (NYSE: AOB) is believed to have an important competitive advantage among Chinese drug manufacturers to wade through pricing uncertainties in healthcare reform, according to Oppenheimer.
Stable drug CPIs help envision a positive outlook for OTC pharmaceuticals, and traditional Chinese medicines continue to lead top pharmacy product sales. Pricing has also remained favorable, as seen in July where traditional Chinese medicines were +11.8% y/y vs. western drugs reports of +0.8%, Oppenheimer reports.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.